Feelnor MR Tablet (Modified Release) 35 mg
Feelnor MR Tablet (Modified Release) 35 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Feelnor MR Tablet (Modified Release) 35 mg |
| Generic | Trimetazidine Dihydrochloride |
| Weight | 35 mg |
| Type | Tablet (Modified Release) |
| Therapeutic Class | Other Anti-anginal & Anti-ischaemic drugs |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Feelnor MR Tablet (Modified Release) 35 mg is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.Dosage
Feelnor MR Tablet (Modified Release) 35 mg dosage
The recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.Side Effects
Trimetazidine is safe and well tolerated. The Common side effects associated with Trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and astheniaPrecaution
Trimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is also not a treatment for myocardial infarction.Interaction
No drug interaction so far has been reported. In particular, no interaction has been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.Pregnancy & Breastfeeding use
There is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.Contraindication
Trimetazidine is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients. It is also is contraindicated in patients with Parkinson’s disease, parkinsonian symptoms, tremors, restless legs movement disorders, severe renal impairment.Storage Condition
Keep in a dry place away from light and heat. Keep out of the reach of children.Innovators Monograph
You find simplified version here Feelnor MR Tablet (Modified Release) 35 mg
